PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.08%
Both companies show declining cash positions (-1.08% vs CRVO's -73.50%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-1.08%
Below half of CRVO's -73.50%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.08%
≥ 1.5x CRVO's -0.27%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.08%
≥ 1.5x CRVO's -0.23%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-18.62%
Less than half of CRVO's 10.68%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.73%
Above 1.5x CRVO's -5.17%. Michael Burry sees a red flag for liquidity risk vs. competitor.
20.52%
Less than half of CRVO's 60.00%. David Dodd sees more deleveraging vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.52%
Less than half of CRVO's 60.00%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
6.94%
Above 1.5x CRVO's 3.10%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-2.13%
0.75-0.9x CRVO's -2.78%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
-79.29%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-7.18%
Below half CRVO's -37.58%. Michael Burry sees potential underperformance in building shareholder capital.
-1.08%
≥ 1.5x CRVO's -0.23%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
20.52%
Less than half of CRVO's -29.43%. David Dodd sees less overall debt expansion vs. competitor.
21.53%
Less than half of CRVO's -29.42%. David Dodd sees better deleveraging or stronger cash buildup than competitor.